Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: A literature-based model analysis of costs in the Italian national health service

Clinical Therapeutics

Volumn 26, Issue 9, 2004, Pages 1546-1561

  Marchetti, Monia ^a   Caruggi, Mauro ^b   Colombo, Giorgio ^c  

^a Medical Center of Pavia   (Italy)

^b BUSTO ARSIZIO HOSPITAL   (Italy)

^c Studi Analisi Valutazioni Economiche   (Italy)

Author keywords

breast cancer; cost utility; cost effectiveness; decision analysis; letrozole; Markov process; nastrozole

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; LETROZOLE; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMMUNITY HOSPITAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DRUG COST; HUMAN; INFORMATION RETRIEVAL; MEDICAL DECISION MAKING; MEDICAL RECORD; MEDICAL SERVICE; POSTMENOPAUSE; QUALITY OF LIFE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; BUDGETS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FEMALE; HUMANS; ITALY; MARKOV CHAINS; MEGESTROL; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; NITRILES; POSTMENOPAUSE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TRIAZOLES;

EID: 9644256101     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.09.014     Document Type: Article

References (76)

1. Negri E., La Vecchia C., and Decarli A. Cancer mortality in Italy, 1997: Quantifying the fall in rates in women and men Tumori 87 2001 290 298
2. Verdecchia A., Micheli A., Colonna M. EUROPREVAL Working Group A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain Ann Oncol 13 2002 1128 1139
3. [published correction appears in Int J Cancer. 2003;107:1058] Sant M., Allemani C., Capocaccia R. EUROCARE Working Group Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe Int J Cancer 106 2003 416 422
4. Buiatti E., Barchielli A., and Bartolacci S. Stage-specific incidence of breast cancer before the beginning of organized screening programs in Italy Cancer Causes Control 13 2002 65 71
5. Wilcken N., Hornbuckle J., and Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer Cochrane Database Syst Rev 2 2003 CD002747
6. Practice Guideline Report 1-5 Members of the Breast Cancer Disease Site Group The Role of Aromatase Inhibitors in the Treatment of Postmenopausal Women with Metastatic Breast Cancer 2003 Cancer Care Ontario, Program in Evidence-Based Care Toronto, Ont
7. Bonneterre J., Thürlimann B., and Robertson J.F. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study J Clin Oncol 18 2000 3748 3757
8. Bonneterre J., Buzdar A., and Nabholtz J.-M. Arimidex Writing Committee Investigators Committee Members Anastrozole is superior to tamoxifen as firstline therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247 2258
9. Milla Santos A., Milla L., and Rallo L. Phase III trial of anastrozole vs tamoxifen in postmenopausal patients with hormone-dependent advanced breast cancer Eur J Cancer 37 Suppl 5 2001 4
10. Mouridsen H., Gershanovich M., and Sun Y. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post menopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101 2109
11. Nabholtz J.M., Buzdar A., Pollak M. Arimidex Study Group Anastrozole is superior to tamoxifen as first-line therapy for advanced breast can cer in postmenopausal women: Results of a North American multicenter randomized trial J Clin Oncol 18 2000 3758 3767
12. de Koning H.J., van Ineveld B.M., and de Haes J.C. Advanced breast cancer and its prevention by screening Br J Cancer 65 1992 950 955
13. Richards M.A., Braysher S., Gregory W.M., and Rubens R.D. Advanced breast cancer: Use of resources and cost implications Br J Cancer 67 1993 856 860
14. Lindgren P., Jonsson B., Redaelli A., and Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: A model for Europe and Australia PharmacoEconomics 20 2002 101 108
15. Geddes M., Carli S., and Ercolanelli M. Colorectal, lung, and breast cancer care during the three years following the diagnosis: A population-based study Tumori 82 1996 210 214
16. Will B.P., Berthelot J.M., and Le Petit C. Estimates of the lifetime costs of breast cancer treatment in Canada Eur J Cancer 36 2000 724 735
17. Wright T. Anastrozole cost-effective in advanced breast cancer PharmacoEcon Outcomes News 147 1998 3 4
18. Henry D., and Lopert R. Pharmacoeconomics and policy decisions: The Australian health care system Clin Ther 21 1999 909 915
19. Veronesi U., Maisonneuve P., Rotmensz N. Italian Tamoxifen Study Group Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women J Natl Cancer Inst 95 2003 160 165
20. Roila F., Ballatori E., and Patoia L. Adjuvant systemic therapies in women with breast cancer: An audit of clinical practice in Italy Ann Oncol 14 2003 843 848
21. Karnon J., and Jones T. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients PharmacoEconomics 21 2003 513 525
22. [published correction appears in J Clin Oncol. 2001;19:3302] Mouridsen H., Gershanovich M., and Sun Y. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2001 2596 2606
23. Rose C., Vtoraya O., and Plunzanska A. Letrozole (Femara) vs anastrozole (Arimidex): Second-line treatment in postmenopausal women with advanced breast cancer Proc Am Soc Clin Oncol 21 2002 34a
24. Milla-Santos A., Milla L., and Portella J. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study Am J Clin Oncol 26 2003 317 322
25. Dranitsaris G., Leung P., Mather J., and Oza A. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to megestrol acetate Anticancer Drugs 11 2000 591 601
26. Dranitsaris G., Verma S., and Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: Comparison of two aromatase inhibitors to tamoxifen Am J Clin Oncol 26 2003 289 296
27. de Haes J.C., de Koning H.J., and van Oortmarssen G.J. The impact of a breast cancer screening programme on quality-adjusted life-years Int J Cancer 49 1991 538 544
28. Hutton J., Brown R., and Borowitz M. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer PharmacoEconomics 9 Suppl 2 1996 8 22
29. Carter K.J., Ritchey N.P., and Castro F. Treatment of early-stage breast cancer in the elderly: A healthoutcome-based approach Med Decis Making 18 1998 213 219
30. Thomas R. Examining quality of life issues in relation to endocrine therapy for breast cancer Am J Clin Oncol 26 2003 S40 S44
31. Decree of the Italian Ministry of Health Assistance Services costs of hospital services [in Italian] Gazzetta Ufficiale (Suppl) September 8, 1997
32. Decree of the Italian Ministry of Health Assistance services costs and specialized outpatient services within the National Health Service [in Italian] Gazzetta Ufficiale (Suppl) September 14, 1996
33. Hospital business from joy to pain [in Italian] Sole 24 ore Sanità November 4-10, 2003 2 3
34. Tas F., Eralp Y., and Basaran M. Anemia in oncology practice: Relation to diseases and their therapies Am J Clin Oncol 25 2002 371 379
35. Abstract Marchetti M., Colombo G., and Carruggi M. Propensity analysis of epoetin use and its impact of overall costs of cancer care Value Health 5 2002 540
36. Abstract Lawless G., Royalty M.W., and Meyers J. Epoetin practice pattem usage in community practice Blood 96 2000 390b
37. Attanasio E., Russo P., Carunchio G., and Caprino L. Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis PharmacoEconomics 19 2001 57 68
38. Lumbardy Region Outpatient Specialist Health Care Services, 2003 2003 National Health Service Lumbardy, Italy
39. Health Ministry of Italy Law 386/74 August 17, 1974
40. Maltoni M., Travaglini C., and Santi M. Evaluation of the cost of home care for terminally ill cancer patients Support Care Cancer 5 1997 396 401
41. Weinstein M.C., Siegel J.E., and Gold M.R. Recommendations of the panel on cost-effectiveness in health and medicine JAMA 276 1996 1253 1258
42. Fenwick E., Claxton K., and Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves Health Econ 10 2001 779 787
43. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 1992 473 481
44. Briggs A.H., Goeree R., Blackhouse G., and O'Brien B.J. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesoph ageal reflux disease Med Decis Making 22 2002 290 308
45. Engel J., Eckel R., and Aydemir U. Determinants and prognoses of locoregional and distant progression in breast cancer Int J Radiat Oncol Biol Phys 55 2003 1186 1195
46. Agency for Regional Health Services Web site November 20. 2003
47. Italian Ministry of Health Financial Act of 2004, Law 350/2003. Provisions for building annual and multiannual state budget Gazetta Ufficiale December 27, 2003
48. Earle C.C., Pham B., and Wells G.A. An assessment of methods to combine published survival curves Med Decis Making 20 2000 104 111
49. Lopert R., Lang D.L., Hill S.R., and Henry D.A. Differential pricing of drugs: A role for cost-effectiveness analysis? Lancet 359 2002 2105 2107
50. Eurispes Web site [in Italian]. Available at: http://www.eurispes.it. Accessed November 25, 2003.
51. Eurostat Web site. Available at: http://www.europa.eu.int/comm/eurostat. Accessed November 25, 2003.
52. Abstract Fricke F.-U., Quednau K., and Pirk O. Letrozole versus tamoxifen as a first-line hormonal therapy in Germany Value Health 5 2002 443
53. Abstract Marchetti M., Liberato N., and Barosi G. First-line therapy for advanced breast cancer. Cost-effectiveness of anastrozole versus tamoxifen Value Health 4 2001 433
54. Hillner B.E., and Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma Cancer 91 2001 484 489
55. Verma S., and Rocchi A. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer Support Care Cancer 19 2003 728 734
56. Nuijten M., Meester L., Waibel F., and Wait S. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK PharmacoEconomics 16 1999 379 397
57. Abstract Annemans L., Moereans K., and Lamarque H. Health economic assessment of the ATATC trial comparing anastrozole versus tamoxifene in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer Value Health 6 2003 625
58. (Suppl) Verma S., Rocchi A., and Cheung S. Canadian cost-effectiveness analysis of anastrozole versus tamoxifen in early breast cancer Abstract 648 Breast Cancer Res Treat 82 2003 S157
59. (Suppl) Hillner B.E. Cost-effectiveness projections of anastrozole vs. tamoxifen as initial adjuvant therapy in ERpositive early breast cancer Abstract 646 Breast Cancer Res Treat 82 2003 S156
60. Brown R.E., Hutton J., and Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK PharmacoEconomics 19 2001 1091 1102
61. Abstract Lilliu H., Le Pen C., and Priol G. Cost-effectiveness of capecitabine in combination with docetaxel monotherapy in patients with advanced and/or metastatic breast cancer in France Value Health 6 2003 626
62. Li N., van Agthoven M., Willemse P., and Uyl-de Groot C. A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer Anticancer Drugs 12 2001 533 540
63. Launois R., Reboul-Marty J., Henry B., and Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine PharmacoEconomics 10 1996 504 521
64. Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer-is it costeffective? Acta Oncol 39 2000 33 39
65. [published correction appears in Eur J Clin Pharmacol. 1997;51:427] Messori A., Becagli P., Trippoli S., and Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer Eur J Clin Pharmacol 51 1996 111 116
66. Hillner B.E., Smith T.J., and Desch C.E. Efficacy and costeffectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using deci sion analysis while awaiting clinical trial results JAMA 267 1992 2055 2061
67. Silber J.H., Fridman M., and Shpilsky A. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer J Clin Oncol 16 1998 2435 2444
68. Dranitsaris G., and Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer Support Care Cancer 7 1999 271 279
69. Abstract Miadi-Fargier H., Trillet-Lenois V., and Ganne C. Impact of innovating and expensive therapies in the treatment of metastatic breast cancer: Focus on trastuzumab (Herceptin) Value Health 5 2002 541
70. Lee J.H., Glick H.A., Hayman J.A., and Solin L.J. Decisionanalytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk pre menopausal breast cancer patients J Clin Oncol 20 2002 2713 2725
71. Dunscombe P., Samant R., and Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients Int J Radiat Oncol Biol Phys 48 2000 977 982
72. Leivo T., Sintonen H., and Tuominen R. The costeffectiveness of nationwide breast carcinoma screening in Finland, 1987-1992 Cancer 86 1999 638 646
73. Available at: Italian Ministry of Health Web site National Drug Formulary 2003 Accessed February 10, 2004
74. Lonning P.E., Bajetta E., and Murray R. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial J Clin Oncol 18 2000 2234 2244
75. Jones S., Vogel C., Arkhipov A. Aromasin Study Group Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer J Clin Oncol 17 1999 3418 3425
76. Weinstein M.C., O'Briend B., and Hornberger J. ISPOR Task Force on Good Research PracticesModeling Studies Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies Value Health 6 2003 9 17